Key Highlights
- Renalytix Plc (LSE: RENX) has spent two years shrinking, refinancing and rebuilding after its Nasdaq exit, largely out of the spotlight.
- On 1 September 2026 the AI-enabled kidney diagnostics group gave the market two reasons to look again: a multi-year collaboration with Quest Diagnostics, one of the largest US laboratory networks.
- The Quest agreement, announced at 07:00 on 1 September 2026, makes kidneyintelX.dkd orderable through existing Quest physician accounts, with samples collected across roughly 2,000 patient service centres and 6,000 in-office phlebotomists.
- Availability is expected in the first quarter of 2027, with Renalytix performing and billing tests from its New York laboratory.
Renalytix Plc (LSE:RENX) has spent two years shrinking, refinancing and rebuilding after its Nasdaq exit, largely out of the spotlight. On 1 September 2026 the AI-enabled kidney diagnostics group gave the market two reasons to look again: a multi-year collaboration with Quest Diagnostics, one of the largest US laboratory networks, and a proposed £9.5m fundraise priced at a 44.6% premium to the previous close. The question is whether national distribution finally converts a clinically validated but commercially slow-burning test, kidneyintelX.dkd, into meaningful revenue. Sales were only about $3m in the year to 30 June 2026, the accounts carry a going-concern warning, and the shares were placed in a temporary "capital access window" halt on LSE while the fundraise was executed.
Quest Diagnostics deal and a premium-priced £9.5m fundraise
The Quest agreement, announced at 07:00 on 1 September 2026, makes kidneyintelX.dkd orderable through existing Quest physician accounts, with samples collected across roughly 2,000 patient service centres and 6,000 in-office phlebotomists. Renalytix says Quest serves around half of US physicians and hospitals. Availability is expected in the first quarter of 2027, with Renalytix performing and billing tests from its New York laboratory. Quest holds an option to in-license the test once certain commercialisation milestones are met, and the fundraise document sets a target of 25,000 tests for 2027 through the partnership. Minutes later the company announced a proposed fundraise of approximately £9.5m (US$12.9m) gross at 6 pence per share, against a 28 August close of 4.15 pence. It comprises a placing of about £6.9m (roughly 115 million shares) through sole bookrunner Oberon Capital, a subscription of about £2.6m (43.3 million shares) from US investors, and a retail offer via the Winterflood WRAP platform. Five directors intend to invest around £260,849. Separately, Heights Capital Management will convert approximately US$4.69m of senior convertible bonds into about 57.4 million shares at the issue price, clearing all Debt to that creditor. Because existing Shareholder authorities were insufficient, the raise is split into two tranches: the first is expected to be admitted on 7 September 2026, the second after a general meeting in late September, with admission expected on 29 September. Proceeds are earmarked for integrating the test into the partner's electronic ordering system, laboratory automation, clinical evidence studies and working capital.
What Renalytix does
Renalytix is an AI-enabled in vitro diagnostics company focused on kidney disease. Its lead product, kidneyintelX.dkd, is a blood test that combines biomarkers with electronic health record data to predict which adults with type 2 diabetes and early-stage chronic kidney disease face progressive kidney function decline. The company says it is the first and only FDA-authorised test for this purpose, addressing roughly 15 million US adults. Revenue comes from commercial testing, reimbursed by Medicare at $950 per reportable result, and from life sciences services, where pharmaceutical companies use the test in drug trials. Growth has been pursued through electronic health record integrations, 2025 collaborations with Tempus AI and MVP Health Care, and now the Quest channel. A CE marking application for Europe was submitted in 2025, with initial testing planned at Denmark's Steno Diabetes Center in late 2026.
Financial performance: revenue growth stalled at $3m
Audited results for the year to 30 June 2025, published on 4 November 2025, showed revenue up 30% to $3.0m from $2.3m. Gross Margin improved to 40% from 9% and administrative expenses fell 40% to $18.4m, helped by headcount cuts and the Nasdaq delisting. The operating loss narrowed to $17.2m from $30.5m and the net loss to $20.4m from $45.5m, or $0.07 per share against $0.42. Year-end cash was $3.6m. The half-year to 31 December 2025, reported on 26 March 2026, showed revenue of $1.6m against $1.3m. Commercial testing slipped to $1.1m from $1.2m, while life sciences revenue rose to $0.5m from $0.1m. Gross margin reached 50%, the operating loss was $7.1m (HY25: $7.5m) and the net loss $8.1m (HY25: $8.6m), or $0.02 per share. Cash stood at $6.1m after a £7.05m gross fundraise in September 2025 and a $4m bond conversion in October 2025, leaving $3.8m of Convertible Bond principal and Negative equity of $1.2m. The board flagged a material uncertainty over going concern. At that point management expected full-year FY26 revenue of about $4.0m. The preliminary, unaudited figure disclosed on 1 September 2026 was approximately $3m, essentially flat on FY25. The company attributed the shortfall to longer implementation cycles at larger multi-site organisations and to resources being redirected towards the strategic collaboration. Audited FY26 results are yet to be published.
What could drive the stock next
The immediate catalysts are mechanical: first-tranche admission on 7 September, the general meeting and second Tranche in late September, and confirmation of the retail offer size. Beyond that, the Quest launch in the first quarter of 2027 is the key operational test, with the 25,000-test target implying a step change from roughly 15,000 patients tested cumulatively to date. Any exercise of Quest's in-licensing option would be a further signal. The new laboratory, completed in April 2026, lifts capacity more than 3.5 times to over 100,000 tests a year and is expected to save more than $2.6m on a net present value basis over five years, so incremental Volume should carry improving gross margin. CE marking, a two-year outcomes study with Wake Forest Atrium Health and Mount Sinai, and pharma services growth are further milestones.
Risks investors should watch
Dilution is the most visible risk. Around 220 million new shares are proposed, including the bond conversion, against 437 million in issue at 31 December 2025, and the second tranche depends on shareholder approval. Renalytix has raised equity in each of the past two Septembers and still reported a going-concern material uncertainty in March 2026; the latest announcement gives no cash figure at 30 June 2026 or runway estimate. Commercial execution has repeatedly lagged. Testing revenue fell in the first half of FY26 and the full year missed the company's own $4m indication, so a partner as large as Quest is no guarantee that physicians will order. The Business also depends on a single Medicare reimbursement rate, a single product and a single US laboratory. Losses remain large relative to revenue, and the shares are Illiquid small-caps on LSE and OTCQB.
Outlook
Renalytix enters its 2027 financial year with a stronger distribution story than at any time since its Nasdaq delisting, a de-levered Balance Sheet if the conversion completes, and a fundraise struck at a premium rather than a discount. Whether that makes it a sleeper stock or another false dawn will be settled by numbers, not partnerships: the audited FY26 results, the post-raise cash position and, above all, test volumes once Quest ordering goes live in early 2027. Investors should watch the general meeting outcome, the retail offer result, and commentary on physician uptake and gross margin at the new laboratory.






Please wait processing your request...